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Abstract
Malaria is one of the most significant causes of morbidity and mortality worldwide. Every year,
nearly one million deaths result from malaria infection. Malaria can be controlled in endemic
countries by using artemisinin-based combination therapy (ACT) in combination with indoor
residual spraying (IRS) and insecticide-treated nets (ITNs). At least 40 malaria-endemic countries
in sub-Saharan Africa now recommend the use of ACT as first-line treatment for uncomplicated
falciparum malaria as a cornerstone of their malaria case management.The scaling up of malaria
control strategies in Zambia has dramatically reduced the burden of malaria. Zambia was the first
African country to adopt artemether/lumefantrine (AL;Coartem®) as first-line therapy in national
malaria treatment guidelines in 2002.Further,the vector control with IRS and ITNs was also scaled
up. By 2008, the rates of in-patient malaria cases and deaths decreased by 61% and 66%,
respectively, compared with the 2001–2002 reference period.
Treatment with AL as first-line therapy against a malaria epidemic in the KwaZulu-Natal province
of South Africa,in combination with strengthening of vector control,caused the number of malaria-
related outpatient cases and hospital admissions to each fall by 99% from 2001 to 2003, and
malaria-related deaths decreased by 97% over the same period. A prospective study also showed
that gametocyte development was prevented in all patients receiving AL. This reduction in malaria
morbidity has been sustained over the past seven years.
AL was introduced as first-line anti-malarial treatment in 2004 in the Tigray region of Ethiopia.
During a major malaria epidemic from May–October 2005, the district in which local community
health workers were operating had half the rate of malaria-related deaths compared with the
district in which AL was only available in state health facilities.Over the two-year study period,the
community-based deployment of AL significantly lowered the risk of malaria-specific mortality by
Open AccessBackground
Malaria is a preventable and treatable disease, yet in
endemic countries in Africa, the consequences of malaria
can be catastrophic. It is thought that approximately half
of the world’s population is currently at risk from malaria
(3.3 billion people) [1]. In 2006, there were an estimated
247 million clinical cases of malaria, 86% of which were
in Africa [2]. Every year, nearly one million deaths result
either directly or indirectly from malaria infection, most
of them in children under five years of age [2]. This is
equivalent to a child dying of malaria in Africa every
30 seconds [3].
In addition to the human burden of malaria, the
economic cost is staggering. Malaria causes an average
loss of 1.3% of annual economic growth in countries with
intense transmission [1], and the estimated economic
burden to African countries is 12 billion USD per year [4].
For a fraction of that sum, malaria could be controlled.
Malaria can be prevented and managed in endemic
countries by using a combination of three main strategies:
indoor residual spraying (IRS), insecticide-treated nets
(ITNs), and treatment with artemisinin-based combina-
tion therapy (ACT). ACT has the unique advantage of
reducing malaria transmission (by decreasing gametocyte
carriage) while curing the disease. Employing tools for
malaria prevention as well as treatment can have a
remarkable impact on the disease burden.
Artemether/lumefantrine (AL; Coartem®) is an ACT that
offers PCR-corrected 28-day cure rates of >95% [5–13], if
given in a six-dose regimen. AL meets the World Health
Organization (WHO) pre-qualification criteria for
efficacy, safety and quality and is the only ACT that has
been approved by ICH stringent regulatory authorities
[14]. A landmark private-public agreement between
Novartis and WHO was unveiled in 2001, whereby
Novartis agreed to make AL available without profit in
malaria-endemic developing countries.
With an increasing number of countries deploying ACT,
the next challenge is to measure the impact these drugs
are having on malaria. Studies designed to measure the
health impact of a particular intervention can be conduc-
ted at different levels of stringency, and a variety of end
points can be used to measure the outcome e.g. all-cause
mortality, malaria-specific mortality, and infection/
gametocyte prevalence. A number of other factors require
careful consideration when evaluating the credibility of
results from trials designed to assess the impact of ACT;
these include changing coverage of other strategic inter-
ventions (e.g. insecticide-treated nets and indoor residual
spraying), and changing diagnostic practices (e.g. intro-
duction of rapid diagnostic tests). To optimize such assess-
ments, studies should collect information from multiple
sites, standardize case definition, and collect data over a pro-
longed period of time. Here, we discuss the results of studies
from South Africa, Zambia and Ethiopia that assessed the
impact of AL on malaria morbidity and mortality.
KwaZulu-Natal province, South Africa: malaria
deaths fell by over 90%
The first large-scale use of AL in Africa was in the
KwaZulu-Natal province of South Africa. During
1995–2000, the area experienced a marked increase in
falciparum malaria, fuelled by a rise in resistance to
pyrethroids used for IRS and to the treatment recom-
mended, sulfadoxine-pyrimethamine. Following rapid
regulatory approval of AL, the drug was launched as first-
line anti-malarial therapy in KwaZulu-Natal in January
2001. The introduction of AL, together with a bold
regional programme for strengthening IRS in both
KwaZulu-Natal and neighbouring southern Mozambique,
had a dramatic effect. Malaria-related outpatient cases
reduced by 85% in 2001 (Figure 1), and by 2003, the
number of malaria-related outpatient cases and hospital
admissions had each fallen by 99%, and malaria-related
deaths had decreased by 97% [15]. This considerable
reduction in the malaria burden has been sustained over
the past 7 years (Figure 2). In a prospective study with 42
days follow-up, AL had a cure rate of 99% and prevented
gametocyte development in all patients. Adherence to the
six-dose AL regimen was reported as 96%, which is
similar to the value (93%) reported in a recent study in
Bangladesh [16].
A cost-effectiveness analysis in the KwaZulu-Natal region
has demonstrated that although AL treatment is more
expensive than SP, its superior cure rate and the reduction
in malaria transmission account for significant cost
savings [17]. Use of AL resulted in an overall reduction in
total malaria expenditure and considerable cost-savings
of US$201,065 in 2002 alone in the one rural hospital
and its nine clinics studied, when compared with SP.
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37%.Additionally, the malaria parasite reservoir was three-fold lower in the intervention district
than in the control district during the 2005 high-transmission season.
Artemisinin-based combination therapy has made a substantial contribution to reducing the burden
of malaria in sub-Saharan Africa.The change in anti-malarial treatment policy to AL in
KwaZulu-Natal has saved a significant number of lives, by
improving clinical and parasitological cure rates and
reducing gametocyte carriage and thus malaria trans-
mission.
Zambia: first African country to deploy
artemether/lumefantrine as first-line treatment
Zambia was the first African country with nationwide
endemic malaria to adopt AL as first-line therapy
according to national malaria treatment guidelines [18].
This is because the 14-day or 28-day failure rates with the
anti-malarial treatment chloroquine in Zambia had
exceeded 40% [19,20]. In 2003, seven pilot districts com-
menced treatment with AL [21], followed by 23 districts
and then nationwide deployment in all 72 districts by
December 2004. The AL was provided free of charge at all
the public health centres countrywide. The proportion of
children treated with AL increased from 10.7% in 2004 to
42% in 2006 [22]. The Zambian Ministry of Health and
partners also took steps to increase vector control efforts
using IRS and ITNs. Between 2003 and 2005, more than
five million nets were distributed, while the number of
structures sprayed increased from 69,774 in 2003 to
657,695 in 2007 [23].
Between 2001 and 2003, the number of malaria deaths
declined from 9,369 to 9,178 (2% reduction; Table 1);
however, after the scale-up of the malaria control efforts
in 2003, the number of malaria-related deaths decreased
from 9,178 to 6,484 between 2003 and 2006 (30% reduc-
tion) [24]. Surveillance data has shown that the rates of
in-patient malaria cases and deaths in 2008 decreased by
61% and 66%, respectively, compared with the reference
period (2001–2002) before the control efforts were
accelerated [21]. Additionally, a cost-effectiveness analysis
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Figure 1
Number of notified cases of confirmed malaria in KwaZulu-Natal by month [15].A indicates reintroduction of
dichlorodiphenyltrichloroethane (DDT) for indoor residual spraying of traditional structures in KwaZulu-Natal; B indicates
introduction of community-based indoor residual spraying in neighbouring Southern Mozambique; C indicates the
implementation of artemether/lumefantrine as first-line therapy in KwaZulu-Natal.
Figure 2
Number of cases of severe and uncomplicated malaria in
Zambia by year (from 18 cost-effectiveness study sites).in Zambia has indicated that the health gains (as defined
by treatment success) from every dollar spent are signifi-
cantly greater if AL is used rather than SP [25]. Another
important finding reported in the study was a 91–93%
reduction in severe malaria cases at health facilities, as
shown in Figure 2 [25].
This investigation revealed no differences in data regis-
tration or the definition of severe malaria between the
retrospective and prospective periods that could account
for this reduction. Severe malaria cases as a proportion of
uncomplicated malaria cases have declined even more
drastically from 2004 to 2005, indicating that fewer cases
than before are progressing to severe malaria [25].
Data from population-based malaria indicator surveys
have confirmed the reduction in malaria morbidity being
recorded at the health facility level. Malaria parasite rates
from a nationally representative sample have reduced by
more than 50% (22% in 2006 versus 10% in 2008) in
children under five years of age [26,27]. Other site specific
data show that parasite prevalence in febrile patients has
decreased from 83% in 2004 to less than 1% in 2008
[28]. Health facility data from the paediatric department
of the Macha Hospital in Southern Zambia has
demonstrated that malaria cases declined by more than
50% between 2003 and 2005 after the introduction of AL,
even before vector control strategies were scaled up in the
area [29]. Malaria experts in Zambia believe that AL has
been a major factor in the reduction in malaria morbidity.
The implementation of effective treatment and large scale
vector control have resulted in reductions in malaria
morbidity and mortality in Zambia, as demonstrated by
both facility and population surveys [23, 26–29]. Main-
taining these strategies is key as Zambia is expected to be
one of the few countries to achieve the Roll Back Malaria
(RBM) target of reducing malaria mortality by half by
2010.
Providing diagnosis and treatment at a local
level through community health workers: the
Tigray project, Ethiopia
A two-year pilot project, commencing in 2005, was
undertaken in Ethiopia to assess how training and equip-
ping local community health workers with AL and rapid
diagnostic tests (RDTs) could help to achieve effective
management of malaria in rural areas. The project took
place in Tigray, the most northern region of Ethiopia
(~80,000 km2) that has a largely rural (81%) population
of approximately 4.5 million. Overall, 56% of the
population of Tigray live in areas in which malaria is
endemic, and less than half of the population live within
easy reach of a health centre [30]. AL was introduced as
first-line anti-malarial treatment in 2004 in the Tigray
region following a high 14-day treatment-failure rate with
SP in Ethiopia (35.9% in 2003; [31]), with large-scale
deployment of ALbeginning in 2005.
Unusually for Africa, Plasmodium falciparum and Plasmo-
dium vivax coexist in the Tigray population. Malaria
transmission is seasonal and hypo-endemic, making the
area vulnerable to epidemics because of the low levels of
immunity within the population.
The Tigray project had two main objectives:
1. To assess the impact of community deployment of AL
on malaria morbidity, hospital admissions, in-patient
deaths, slide positivity rate, mortality and health
services utilization.
2. To assess the feasibility and impact of phased intro-
duction of community-based rapid diagnostic tests to
confirm diagnosis of malaria before the adminis-
tration of AL.
To examine the impact of community deployment of AL,
the study area was divided into two districts (Figure 3). In
the control district (Raya Azebo), standard malaria case-
management continued, with AL being prescribed at
health facilities but not at the community level. In the
first year of the study in the intervention district
(Alamata), early clinical diagnosis of malaria and
deployment of AL was conducted by 33 community
health workers (CHWs) as well as by health workers in
health facilities. Volunteers were chosen to act as CHWs,
and were trained in correct clinical diagnosis of malaria,
administration of AL, and community education. In the
second year of the study, CHWs were provided with RDTs
to help ensure that AL was only given to patients with
malaria due to P. falciparum, with the aims of minimizing
the risk of resistance developing and improving cost
effectiveness by countering excessive and unnecessary
administration of AL.
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Table 1 – Number of all-cause and malaria-related deaths in Zambia
from 2001–2006 [24].
All age-groups (including under 5 years of age) 
Total Total  Total  malaria
all-cause  malaria attributed  as a proportion 
Year deaths probable deaths (%) of all deaths
2001 35358 9369 26.50
2002 39482 9021 22.85
2003 39117 9178 23.46
2004 38466 8289 21.55
2005 38740 7737 19.97
2006 35541 6484 18.24During the project, which involved over 200,000 indivi-
duals presenting with malaria-related symptoms, 58% of
patients in the intervention district were treated for
malaria by CHWs instead of at health facilities, thus
reducing the malaria case load for general health services.
A lower rate of P. falciparum-positive cases was reported in
the intervention district compared with the control district
(48% of 4,778 blood slides versus 64% of 6,778 blood
slides over the two-year study, respectively). During a major
malaria epidemic from May–October 2005, the district in
which the local volunteers were operating had approxi-
mately half the rate of malaria-related deaths compared
with the district in which AL was available only in state
health facilities (24 out of 991 deaths in the intervention
district, versus 53 out of 1106 deaths in the control district)
[32]. Over the two-year period, the community-based
deployment of AL significantly lowered the risk of
malaria-specific mortality by approximately 37%
(p=0.013). Additionally, the malaria parasite reservoir was
three-fold lower in the intervention district than in the
control district during the 2005 high-transmission season
(Figure 4). The use of RDTs by CHWs in the second year of
the study allowed exclusion of non-P. falciparum malaria in
89.7% of cases, avoiding over-treatment with AL.
Community deployment of AL ensured that patients
could be treated promptly, with access to effective therapy
at all times. Overall, the intervention was associated with
lower malaria transmission, a lower malaria case burden
for health facilities, and reduced malaria morbidity and
mortality.
The use of ACT in Africa
Following the launch of the WHO ‘Roll Back Malaria’
campaign in 1998, few countries with endemic malaria
had adopted ACT by 2000. The turning point came in
January 2004, when an article was published in The
Lancet [33], a constructive criticism of the lack of policy
change written by prominent opinion leaders. A more
rapid adoption of ACT since the beginning of 2004
resulted in at least 40 malaria-endemic countries in sub-
Saharan Africa rapidly scaling up malaria prevention and
treatment and recommending the use of ACT as first-line
treatment for uncomplicated falciparum malaria [34].
Now is a critical time to establish the impact and
sustainability of malaria control in Africa. AL continues to
be provided in malaria-endemic African countries by
Novartis on a non-profit basis, and more than 250
million AL treatments have been supplied to developing
countries to date. The effect on patients is significant;
African communities carrying the highest burden of
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Figure 3
The Tigray Project Study Design.
Figure 4
Malaria parasite reservoir in the control and intervention
districts of the Tigray study region. Malaria parasite reservoir
was three-fold lower in the intervention district during 2005
high-transmission season.malaria are increasingly able to access effective
artemisinin-based combination therapy using locally
available delivery models. Access to effective treatment
reduces the risk of malaria mortality.
Conclusions
Artemether-lumefantrine has had a remarkable impact in
South Africa, Zambia and Ethiopia. Similar benefits have
been seen with other forms of ACT, particularly
artesunate-mefloquine on the western border of Thailand
[35] and artesunate-amodiaquine in Zanzibar [36]. These
parallel findings indicate that the public health impact is
a class effect of the artemisinin-based combinations, and
can be achieved when high rates of coverage and
adherence are accomplished and the partner drug is
highly effective.
Malaria is a life-threatening but fully preventable and
treatable disease. By scaling up malaria control measures,
the health and economic impact of the disease in Africa
can be significantly reduced [37]. The impact of ACT on
the disease, the synergistic effect on other control
strategies and the healthcare benefits are being realized.
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